Please assess the completion status of the following clinical trial:

Trial Title: Nelfinavir in Systemic Lupus Erythematosus

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~1. Subject is capable of providing written informed consent~2. Subject is ≥ 18 years old and ≤ 65 years old~3. Meets at least 4 of 11 modified American College of Rheumatology (ACR) (1997) Revised Criteria for the Classification of Systemic Lupus Erythematosus~4. Has mild to moderate disease activity defined as~   * A minimum SLEDAI score of 2 excluding points for serology (anti-dsDNA antibody and complement)~  * No active renal or nervous system disease~  * No BILAG A in any organ system~  * No expectation by the investigator that corticosteroids will need to be added or doses increased during the 8 week treatment period for any reason~  * No expectation by the investigator that immunosuppressive medication will need to be added or doses increased during the 8 week treatment period~5. Has elevated titers of anti-ds DNA antibody at the time of screening (defined as the titer that meets criteria for high in the Core Laboratory at the North Shore/LIJ Health Systems; unequivocal high titer as opposed to borderline, indeterminate or intermediate).~6. Has elevated titers of cross-reactive anti-DNA/DWEYS antibodies at the time of screening (the assays for anti-DNA/DWEYS antibodies will be performed in Dr. B. Diamond's laboratory; study sites will be notified of results within 3 days of receipt of the samples).~7. If on glucocorticoids, the dose must be ≤10 mg daily and stable for the 4 weeks prior to screening and baseline~8. If on immunosuppressive or immunomodulatory medication such as azathioprine, methotrexate, leflunomide, mycophenolate, or hydroxychloroquine, the dose must have been stable for the 3 months prior to screening, and expected to remain stable over the course of the study.~9. Males and females with potential for reproduction must agree to practice effective birth control measures (2 approved methods of contraception). Nelfinavir can decrease serum levels of oral contraceptives; the slightly increased risk of pregnancy due to an interaction between oral contraception and nelfinavir will be discussed when appropriate and the requirement for a second approved method of contraception will be addressed.~Exclusion Criteria:~1. Current or prior treatment with rituximab, belimumab or anti-CD22 monoclonal antibody in the 12 months prior to this study or any other biologic agent for 90 days prior to this study~2. Treatment with cyclophosphamide within the 6 months prior to screening~3. Increase in glucocorticoid dose within 4 weeks of screening or addition of a DMARD in the three months prior to study~4. A history of drug or alcohol abuse within the 6 months prior to screening~5. Elevated LFT's:~   * ALT or AST ≥ 2 x upper limit of normal at screening~  * serum unconjugated bilirubin \> 3mg/dL at screening~6. Dialysis or serum creatinine \>1.5mg/dL~7. Hypercholesterolemia: total cholesterol \>230 mg/dL or LDL \>150 mg/dl or hypertriglyceridemia (triglyceride \>200mg/dL) at screening~8. Laboratory/clinical evidence of: pancreatitis: amylase/lipase \>3x upper limit of normal at screening~9. Known current/active infections including HIV, Hepatitis B, Hepatitis C~10. History of cancer, excluding skin cancers (squamous cell or basal cell that have been treated)~11. Known active tuberculosis or untreated tuberculosis~12. Hemoglobin \< 8 g/dL~13. Expectation by the investigator to increase corticosteroid or immunosuppressive, or immunomodulatory medication dose at screening, baseline, or over the course of the study~14. Pregnancy or lactation~15. Consumption of \> 2 cups of grapefruit juice per day~16. Treatment with medications metabolized using the cytochrome P3A4 pathway, such as cyclosporine, tacrolimus, gemfibrozil, niacin, itraconazole, ketoconazole, erythromycin, azithromycin, clarithromycin, bosentan, nefazodone, tricyclic antidepressants~17. Any condition that, in the opinion of the Investigator, would jeopardize the subject's safety following exposure to the study drug.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- nelfinavir (Type: EXPERIMENTAL): Nelfinavir tablets will be taken by oral administration, 750mg (three 250 mg tablets) three times a day

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy